Adalvo continues to expand its specialty generics portfolio with the development of Voclosporin Soft Gel Capsules, a calcineurin inhibitor (CNI) indicated for the treatment of active lupus nephritis (LN) in adults.
The global dossier is on track for completion by Q4 2025, highlighting Adalvo’s commitment to bringing high-quality differentiated treatment options to patients worldwide.
Voclosporin represents the first FDA-approved oral therapy for patients with active Lupus Nephritis.
According to IQVIA, global INN sales for Voclosporin reached $219 million in 2024, with peak sales forecast to reach $600 million by 2028 (GlobalData).
By leveraging our regulatory expertise and global reach, Adalvo is positioned to expand access to this important treatment.
Click Here to Contact Our Team to Discuss Strategic Partnerships
Partner up now!